Table 2.

Main prospective trials of trabectedin in STS patients

Author	Phase	No of patients	Dose schedule	Response rate (%)	Median TTP (months)	6-Month PFS (%)	Median OS (months)
Yovine et al43	II	54	1.5 mg/m2 24-hour infusion q3w	4	1.9	24	12.8
Garcia-Carbonero et al44	II	36	1.5 mg/m2 24-hour infusion q3w	8	1.7	23	12.1 (1-year OS 53%)
Le Cesne et al45	II	104	1.5 mg/m2 24-hour infusion q3w	8	3.4	29	9.2
Demetri et al13	II	270	2 arms:	5.6	3.7	35.5	13.9
			1.5 mg/m2 24-hour infusion q3w 0.58 mg/m2 3-hour infusion each week for 3 out of 4 weeks	1.6	2.3	27.5	11.8
Demetri et al13	III	518	1.5 mg/m2 24-hour infusion q3w	9.9	1	37	12.4

Abbreviations: STS, soft tissue sarcoma; TTP, time to progression; PFS, progression-free survival; OS, overall survival; q3w, every 3 weeks.